SAN

93.09

-3.18%↓

EI

238.4

-2.34%↓

SHL.DE

43.71

-1.75%↓

ARGX

497.9

-4.29%↓

FRE

36.5

-4%↓

SAN

93.09

-3.18%↓

EI

238.4

-2.34%↓

SHL.DE

43.71

-1.75%↓

ARGX

497.9

-4.29%↓

FRE

36.5

-4%↓

SAN

93.09

-3.18%↓

EI

238.4

-2.34%↓

SHL.DE

43.71

-1.75%↓

ARGX

497.9

-4.29%↓

FRE

36.5

-4%↓

SAN

93.09

-3.18%↓

EI

238.4

-2.34%↓

SHL.DE

43.71

-1.75%↓

ARGX

497.9

-4.29%↓

FRE

36.5

-4%↓

SAN

93.09

-3.18%↓

EI

238.4

-2.34%↓

SHL.DE

43.71

-1.75%↓

ARGX

497.9

-4.29%↓

FRE

36.5

-4%↓

Search

Innate Pharma SA

Abierto

1.598 -5.89

Resumen

Variación precio

24h

Actual

Mínimo

1.29

Máximo

1.698

Métricas clave

By Trading Economics

Ingresos

-25M

Ventas

12M

Margen de beneficios

-200.599

Empleados

181

EBITDA

-26M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+155.7% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

159M

Apertura anterior

7.49

Cierre anterior

1.598

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Innate Pharma SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 abr 2025, 22:38 UTC

Acciones populares

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

7 abr 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy: Stonepeak's Total Contribution Lower Than Nominal Equity Interest Give Accelerated Spend

6 abr 2025, 23:58 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy: Deal 'a Material Step' Toward Readiness for Final Investment Decision

6 abr 2025, 23:58 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy: Deal 'Significantly Reduces' Company's Capex Profile

6 abr 2025, 23:57 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy: Stonepeak to Contribute 75% of Project Capex in Both 2025, 2026

6 abr 2025, 23:57 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy: Stonepeak to Provide $5.7 Billion Towards Expected Project Capex

6 abr 2025, 23:57 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 abr 2025, 23:57 UTC

Charlas de Mercado

Nervous Start For AUD/USD; Watch on CNY Fix -- Market Talk

6 abr 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Woodside Energy: Signs Deal With Stonepeak for Sale of 40% Interest in Louisiana LNG Infrastructure

6 abr 2025, 23:52 UTC

Charlas de Mercado

Gold Slips; Likely Unwinding of Long Positions to Raise Cash -- Market Talk

6 abr 2025, 23:39 UTC

Charlas de Mercado

Oil Futures Slide on Fears of Weakening Global Demand -- Market Talk

6 abr 2025, 23:39 UTC

Charlas de Mercado

Nikkei May Fall as U.S. Tariffs Weigh on Global Econ Outlook -- Market Talk

6 abr 2025, 23:39 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

6 abr 2025, 23:38 UTC

Adquisiciones, fusiones, absorciones

Challenger: Reinsurance Relationship With MS Primary Will Continue

6 abr 2025, 23:38 UTC

Adquisiciones, fusiones, absorciones

Challenger: Acquisition at 53% Premium to Most Recent Share Price

6 abr 2025, 23:37 UTC

Adquisiciones, fusiones, absorciones

Challenger: Acquisition Subject to Regulatory Approvals

6 abr 2025, 23:36 UTC

Adquisiciones, fusiones, absorciones

Challenger: Dai-ichi Life Acquiring Stake From MS&AD Insurance

6 abr 2025, 23:36 UTC

Adquisiciones, fusiones, absorciones

Challenger: Dai-ichi Life Paying About A$8.46/Share

6 abr 2025, 23:35 UTC

Adquisiciones, fusiones, absorciones

Challenger: Dai-ichi Life Agrees to Acquire 15.1% Interest

6 abr 2025, 21:58 UTC

Principales Noticias

Bitcoin Is Falling Amid Global Market Swoon -- Barrons.com

6 abr 2025, 13:00 UTC

Principales Noticias

Trump Promised to Lower Energy Prices -- But It Wasn't Supposed to Be Like This -- WSJ

5 abr 2025, 15:45 UTC

Principales Noticias

Republicans Advance Trump's Tax Cuts After Late-Night Session -- Update

5 abr 2025, 15:00 UTC

Principales Noticias

U.S.-Stock Funds Have a Quarter to Forget -- Journal Report

5 abr 2025, 15:00 UTC

Principales Noticias

The Complicated Relationship Between Consumer Sentiment and Stocks -- Journal Report

5 abr 2025, 14:38 UTC

Principales Noticias

Trump's Trade Broadside Puts Chinese Economy Under Heavy Pressure -- WSJ

5 abr 2025, 06:44 UTC

Principales Noticias

Republicans Advance Trump's Tax Cuts After Late-Night Session -- WSJ

5 abr 2025, 01:00 UTC

Adquisiciones, fusiones, absorciones

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ

5 abr 2025, 01:00 UTC

Adquisiciones, fusiones, absorciones

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ -2-

4 abr 2025, 21:53 UTC

Charlas de Mercado

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 abr 2025, 21:44 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

Comparación entre iguales

Cambio de precio

Innate Pharma SA previsión

Precio Objetivo

By TipRanks

155.7% repunte

Estimación a 12 Meses

Media 4.398 EUR  155.7%

Máximo 5.7 EUR

Mínimo 3.1 EUR

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innate Pharma SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

1

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 1.854Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.